Category: Gastro-Hep News
Gastro-Hep News
US Food and Drug Administration Approves 8-Week Treatment for Pangenotypic Hepatitis C Virus Infection On August 3, 2017, the US Food and Drug Administration (FDA) approved […]
Gastro-Hep News
US Food and Drug Administration Approves Treatment for Chronic Hepatitis C Virus Genotypes 1 Through 6 On July 18, 2017, the US Food and Drug Administration […]
Gastro-Hep News
Higher Risk of Interval Colorectal Cancer Found Among Older Black Patients Older black patients have a higher risk for interval colorectal cancer (CRC), particularly cancer of […]
Gastro-Hep News
US Food and Drug Administration Approves Infliximab Biosimilar On April 21, 2017, the US Food and Drug Administration (FDA) approved infliximab-abda (Renflexis, Samsung Bioepis), an infliximab […]
Gastro-Hep News
Committee for Medicinal Products for Human Use Votes for 8-Week Treatment Option for Hepatitis C Virus Infection On February 28, 2017, the Committee for Medicinal Products […]
Gastro-Hep News
Gastroenterology & Hepatology Volume 12, Issue 9, September 2016 Samantha Alleman US Food and Drug Administration Approves Dexlansoprazole for Adolescent Patients With Gastroesophageal Reflux Disease On […]
Gastro-Hep News
Gastroenterology & Hepatology Volume 12, Issue 6, June 2016 Samantha Alleman Daclatasvir/Sofosbuvir/Ribavirin Effective for Patients With Hepatitis C Virus Genotype 3 Infection With Advanced Liver Disease […]
Gastro-Hep News
Gastroenterology & Hepatology Volume 12, Issue 5, May 2016 Samantha Alleman Obeticholic Acid Drug Receives Accelerated Approval Recommendation From FDA Advisory Committee The Gastrointestinal Drugs Advisory […]
Gastro-Hep News
Gastroenterology & Hepatology April 2016, Volume 12, Issue 4 Samantha Alleman European Medicines Agency Reviewing Direct-Acting Antiviral Agents for Hepatitis B Virus Reactivation The European Medicines […]
Gastro-Hep News
Gastroenterology & Hepatology March 2016, Volume 12, Issue 3 Samantha Alleman Proton Pump Inhibitor Use Related to Increased Dementia Risk Proton pump inhibitors (PPIs) are associated […]
Gastro-Hep News
Gastroenterology & Hepatology February 2016, Volume 12, Issue 2 Samantha Alleman The 2016 Gastrointestinal Cancers Symposium was held January 21-23 in San Francisco, California. Below is […]
Gastro-Hep News
Gastroenterology & Hepatology January 2016, Volume 12, Issue 1 Samantha Alleman Sofosbuvir/Velpatasvir With or Without Ribavirin Effective for HCV in Patients With Any Genotype and Decompensated […]
Gastro-Hep News
Gastroenterology & Hepatology December 2015, Volume 11, Issue 12 Samantha Alleman Sofosbuvir/Velpatasvir With or Without Ribavirin Effective for HCV in Patients With Any Genotype and Decompensated […]
Gastro-Hep News
Gastroenterology & Hepatology November 2015, Volume 11, Issue 11 Devon Schuyler, ELS Ledipasvir/Sofosbuvir Plus Ribavirin Effective for Hepatitis C Virus in Patients With Advanced Liver Disease […]
Gastro-Hep News
Gastroenterology & Hepatology September 2015, Volume 11, Issue 9 Samantha Alleman High Concentration of Infliximab in Feces Linked to Reduced Response to Ulcerative Colitis […]
Gastro-Hep News
Gastroenterology & Hepatology August 2015, Volume 11, Issue 8 Samantha Alleman Sitafloxacin-Based Triple Therapy Developed to Treat Helicobacter pylori–Positive Patients In a study published […]
GASTRO-HEP News
Gastroenterology & Hepatology April 2014, Volume 10, Issue 4 By Dee Rapposelli National Colorectal Cancer Roundtable Launches Initiative to Achieve 80% Colorectal Cancer Screening Rate by 2018 […]
Highlights From AASLD 2013
HIGHLIGHTS FROM AASLD 2013 By Dee Rapposelli Interim Results of Investigational NS3/4A Protease Inhibitor/NS5A Replication Complex Inhibitor Combo in HCV GT 1a/b Infection Interim results of […]
Highlights From ACG 2013
Highlights From ACG 2013 By Dee Rapposelli The American College of Gastroenterology Debuts ACG Hepatitis Circle To provide tools to manage patients with hepatitis C virus (HCV) infection […]
GASTRO-HEP News
GASTRO-HEP News By Dee Rapposelli FDA Mandates Black Box Warning of HBV Infection Risk for 2 Leukemia Therapies Although labeling for both ofatumumab (Arzerra, Glaxo-SmithKline) and rituximab […]